Study Information

About the study

We’re investigating a potential new treatment for Cryopyrin Associated Periodic Syndrome (CAPS), a condition in which the body fails to adequately regulate inflammation.

CAPS is an inherited disease caused by a gene mutation that results in a defect in cryopyrin, a protein that plays in an important role in controlling inflammation. CAPS occurs in all age groups in both men and women and causes episodes of fever, a hive-like rash; joint pain and swelling; red eyes and headaches.

The purpose of this research is to determine if the study drug acts to reduce the harmful effects of inflammation. Current available therapies for CAPS are all injectable whereas we are investigating a small molecule medication which can be given by mouth in the form of capsules.

Participants will be reimbursed $3,500 for their participation in this study and this clinical trial has been approved by an independent ethics committee.

How do I find out more?

If you would like more information about this study, please call 1800 243 733 or 03 8593 9878. You can also email us at quoting “CAPS Study”.

  • 9
    Nights Inpatient Stay
  • 1
    Outpatient Visit

Minimum Eligibility Requirements:

  • Males and Females
  • Confirmed diagnosis of Cryopyrin-Associated Periodic Syndrome (CAPS)
  • Aged 18 – 70 years old

More Patient Volunteer Studies

Other Studies You Might be Interested In